TGCT is a rare condition that can be difficult to live with and frustrating to treat

Study Banner Study Banner

People depicted are not actual patients or HCPs.

Tenosynovial giant cell tumor (TGCT) is typically a non-malignant neoplasm that can be locally aggressive1

While TGCT may be non-malignant, it is still a chronic and debilitating disease that may lead to life-altering joint damage and disability2,3

Estimated recurrence rates after resection

Incidence and prevalence of TGCT

It is unknown how many people are currently living with this rare disease, but worldwide estimates were extrapolated from a study in the Netherlands.

Diffuse TGCT developing
in a knee joint

Localized (GCT-TS) Estimated 39 cases
per million person-years
~13,000 patients in the
United States in 20196,7


DIFFUSE (PVNS) Estimated 4 cases
per million person-years
~1300 patients in the
United States in 20196,7


NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend that—prior to the initiation of therapy—all patients be evaluated and managed by a multidisciplinary team with expertise and experience in sarcoma8

Complete resection should be considered but isn't always an option

Surgical outcomes depend on many factors, including localization and extent of the disease and patient characteristics1,4,9

Recurrence rates in diffuse TGCT have been seen as high as4

Diffuse TGCT may lead to invasive surgical resection and deteriorating quality of life due to recurrence1

Many patients may
require multiple surgeries.
This can lead to6,10,11:

Pain11 Reduced
function of the
affected joints6,11,12
Possible joint
replacement or
Increased risk
of infection6

Because of the locally aggressive and recurrent nature of TGCT, multiple surgeries may be
required and may lead to a decline in functional outcome and a severe decline in quality of life.2,5,6

Learn how to identify potential TURALIO patients

Interested in TURALIO?

Get more information and resources


References: 1. Mastboom MJL et al. Surg Oncol. 2018;27(3):544-550. 2. Cook NS et al. Adv Ther. 2020;37:2813-2828. 3. Mastboom MJ et al. Interact J Med Res. 2018;7(1):e4. 4. Ehrenstein V et al. J Rheumatol. 2017;44(10):1476-1483. 5. Van der Heijden L et al. Bone Joint J. 2014;96-B(8):1111-1118. 6. Mastboom MJL et al; TGCT study group. Acta Orthop. 2017;88(6):688-694. 7. 2017 National Population Projections Tables: Main Series. United States Census Bureau; 2017. Accessed October 20, 2021. 8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 9. Palmerini E et al. Eur J Cancer. 2015;51(2):210-217. 10. Benner B et al. Drug Des Devel Ther. 2020;14:1693-1704. 11. Gelderblom H et al. Future Oncol. 2020;16(29):2345-2356. 12. Mastboom MJL et al. Lancet. 2019;20(6):877-886.